Business
Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip
Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"GenAccord!™ Offers Newly Innovative \"Either / Or\" Technology, Allowing the Test Strip to Work on More Than One Legacy Diabetic MeterLOS ANGELES, CA / ACCESSWIRE / December 20, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ (\"Sunshine\") diabetes test strip, the new internationally launched GenSure!™ (\"Feather\") diabetes test strip, and the clinical trial ready GenChoice!™ \"Ladybug\" diabetes test strip, as well as three other unique test strips and meters in development, including our panacea strip and meter system the highly innovative GenPrecis! ™.Today, DECN previews the GenAccord!™ test strip, the company's latest product addition to its suite of blood glucose test strips. GenAccord!™ significantly becomes the company's first derivative product expansion employing the GenPrecis!™ full spread electro-chemistry technology.Keith Berman, CEO of Decision Diagnostics, commented, \"GenAccord!™ is a significant technological advancement. Rather than being limited to a single test meter or family of test meters made by a single legacy manufacturer, GenAccord!™ is adaptive to multiple different generations of meters where the glucose chemistries are similar. Remarkably, this strip works precisely and accurately with new meter technology or with vintage meters. It features the flexibility of functioning with meters made by the same or different legacy manufacturers, regardless of generation or vintage, since many meter and strip systems evolved from the same technology roots. Each GenAccord!™ test strip would operate with two different meter combinations.\"Mr. Berman continued, \"There are approximately 29 million glucometers in use worldwide. GenAccord!™ could reasonably generate $65 million annually in the traditional Type II marketplaces, and an additional $17 million annually in Type 1, Gestational, and Type 1.5 marketplaces with net profits approaching 20%. GenAccord!™ will initially be compatible with products manufactured by one strong worldwide industry leader, meters and test strip systems currently used by approximately 800,000 diabetics worldwide. This ...